and build a global multi-field drug research and development platform.
The advisory team includes authoritative experts in gene therapy, clinicians from top-tier tertiary hospitals, and executives of listed pharmaceutical companies. Based on the law of new drug development, the company has formed a new drug development team with strong R&D and industrialization capabilities. The team includes CMC, quality, QA, and R&D departments.
The company's internationally leading innovative technology platforms BDlenti and BDmRNA have received extensive attention from research institutions and pharmaceutical companies at home and abroad, promoting the company's growth into a top biopharmaceutical company. The company has multiple indications such as HSK, thalassaemia, wAMD and so on.
The company now has a laboratory of about 1,000 square meters, with good experimental conditions and a comfortable working environment.
Researcher and assistant dean of Shanghai Jiaotong University
He has long been engaged in research work on gene therapy virus vectors, gene editing delivery technology, etc., striving to transform new technologies into clinical treatments.His research papers have been published in journals such as Nature Biotechnology, Nature Biomedical Engineering, Nature Immunology, etc.